table of content
1 Study Coverage
1.1 Immuno-oncology Drugs Product Introduction
1.2 Global Immuno-oncology Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Immuno-oncology Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Immuno-oncology Drugs Sales in Volume for the Year 2017-2028
1.3 United States Immuno-oncology Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Immuno-oncology Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Immuno-oncology Drugs Sales in Volume for the Year 2017-2028
1.4 Immuno-oncology Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Immuno-oncology Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Immuno-oncology Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Immuno-oncology Drugs Market Dynamics
1.5.1 Immuno-oncology Drugs Industry Trends
1.5.2 Immuno-oncology Drugs Market Drivers
1.5.3 Immuno-oncology Drugs Market Challenges
1.5.4 Immuno-oncology Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Immuno-oncology Drugs Market Segment by Type
2.1.1 Immune Checkpoint Inhibitors
2.1.2 Immune System Modulators
2.1.3 Cancer Vaccines
2.1.4 Oncolytic Virus
2.1.5 Others
2.2 Global Immuno-oncology Drugs Market Size by Type
2.2.1 Global Immuno-oncology Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Immuno-oncology Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Immuno-oncology Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Immuno-oncology Drugs Market Size by Type
2.3.1 United States Immuno-oncology Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Immuno-oncology Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Immuno-oncology Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Immuno-oncology Drugs Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Ambulatory Surgical Centers
3.2 Global Immuno-oncology Drugs Market Size by Application
3.2.1 Global Immuno-oncology Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Immuno-oncology Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Immuno-oncology Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Immuno-oncology Drugs Market Size by Application
3.3.1 United States Immuno-oncology Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Immuno-oncology Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Immuno-oncology Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Immuno-oncology Drugs Competitor Landscape by Company
4.1 Global Immuno-oncology Drugs Market Size by Company
4.1.1 Top Global Immuno-oncology Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Immuno-oncology Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Immuno-oncology Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Immuno-oncology Drugs Price by Manufacturer (2017-2022)
4.2 Global Immuno-oncology Drugs Concentration Ratio (CR)
4.2.1 Immuno-oncology Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Immuno-oncology Drugs in 2021
4.2.3 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Immuno-oncology Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Immuno-oncology Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Immuno-oncology Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Immuno-oncology Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Immuno-oncology Drugs Market Size by Company
4.5.1 Top Immuno-oncology Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Immuno-oncology Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Immuno-oncology Drugs Sales by Players (2020, 2021 & 2022)
5 Global Immuno-oncology Drugs Market Size by Region
5.1 Global Immuno-oncology Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Immuno-oncology Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Immuno-oncology Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Immuno-oncology Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Immuno-oncology Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Immuno-oncology Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Immuno-oncology Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Immuno-oncology Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Amgen, Inc
7.1.1 Amgen, Inc Corporation Information
7.1.2 Amgen, Inc Description and Business Overview
7.1.3 Amgen, Inc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Amgen, Inc Immuno-oncology Drugs Products Offered
7.1.5 Amgen, Inc Recent Development
7.2 AstraZeneca, Plc
7.2.1 AstraZeneca, Plc Corporation Information
7.2.2 AstraZeneca, Plc Description and Business Overview
7.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 AstraZeneca, Plc Immuno-oncology Drugs Products Offered
7.2.5 AstraZeneca, Plc Recent Development
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Corporation Information
7.3.2 Bristol-Myers Squibb Description and Business Overview
7.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Products Offered
7.3.5 Bristol-Myers Squibb Recent Development
7.4 Celgene Corporation
7.4.1 Celgene Corporation Corporation Information
7.4.2 Celgene Corporation Description and Business Overview
7.4.3 Celgene Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Celgene Corporation Immuno-oncology Drugs Products Offered
7.4.5 Celgene Corporation Recent Development
7.5 Eli Lilly and Company
7.5.1 Eli Lilly and Company Corporation Information
7.5.2 Eli Lilly and Company Description and Business Overview
7.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Eli Lilly and Company Immuno-oncology Drugs Products Offered
7.5.5 Eli Lilly and Company Recent Development
7.6 Merck & Co.
7.6.1 Merck & Co. Corporation Information
7.6.2 Merck & Co. Description and Business Overview
7.6.3 Merck & Co. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Merck & Co. Immuno-oncology Drugs Products Offered
7.6.5 Merck & Co. Recent Development
7.7 Hoffmann-La Roche AG
7.7.1 Hoffmann-La Roche AG Corporation Information
7.7.2 Hoffmann-La Roche AG Description and Business Overview
7.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Products Offered
7.7.5 Hoffmann-La Roche AG Recent Development
7.8 Johnson & Johnson
7.8.1 Johnson & Johnson Corporation Information
7.8.2 Johnson & Johnson Description and Business Overview
7.8.3 Johnson & Johnson Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Johnson & Johnson Immuno-oncology Drugs Products Offered
7.8.5 Johnson & Johnson Recent Development
7.9 Novartis International AG
7.9.1 Novartis International AG Corporation Information
7.9.2 Novartis International AG Description and Business Overview
7.9.3 Novartis International AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Novartis International AG Immuno-oncology Drugs Products Offered
7.9.5 Novartis International AG Recent Development
7.10 AbbVie, Inc.
7.10.1 AbbVie, Inc. Corporation Information
7.10.2 AbbVie, Inc. Description and Business Overview
7.10.3 AbbVie, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 AbbVie, Inc. Immuno-oncology Drugs Products Offered
7.10.5 AbbVie, Inc. Recent Development
7.11 Pfizer Inc.
7.11.1 Pfizer Inc. Corporation Information
7.11.2 Pfizer Inc. Description and Business Overview
7.11.3 Pfizer Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Pfizer Inc. Immuno-oncology Drugs Products Offered
7.11.5 Pfizer Inc. Recent Development
7.12 Sanofi S.A.
7.12.1 Sanofi S.A. Corporation Information
7.12.2 Sanofi S.A. Description and Business Overview
7.12.3 Sanofi S.A. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Sanofi S.A. Products Offered
7.12.5 Sanofi S.A. Recent Development
7.13 EMD Serono, Inc.
7.13.1 EMD Serono, Inc. Corporation Information
7.13.2 EMD Serono, Inc. Description and Business Overview
7.13.3 EMD Serono, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 EMD Serono, Inc. Products Offered
7.13.5 EMD Serono, Inc. Recent Development
7.14 Gilead Sciences Inc.
7.14.1 Gilead Sciences Inc. Corporation Information
7.14.2 Gilead Sciences Inc. Description and Business Overview
7.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Gilead Sciences Inc. Products Offered
7.14.5 Gilead Sciences Inc. Recent Development
7.15 Prometheus Therapeutics & Diagnostics
7.15.1 Prometheus Therapeutics & Diagnostics Corporation Information
7.15.2 Prometheus Therapeutics & Diagnostics Description and Business Overview
7.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Prometheus Therapeutics & Diagnostics Products Offered
7.15.5 Prometheus Therapeutics & Diagnostics Recent Development
7.16 Aduro BioTech
7.16.1 Aduro BioTech Corporation Information
7.16.2 Aduro BioTech Description and Business Overview
7.16.3 Aduro BioTech Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Aduro BioTech Products Offered
7.16.5 Aduro BioTech Recent Development
7.17 Galena Biopharma
7.17.1 Galena Biopharma Corporation Information
7.17.2 Galena Biopharma Description and Business Overview
7.17.3 Galena Biopharma Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Galena Biopharma Products Offered
7.17.5 Galena Biopharma Recent Development
7.18 Bavarian Nordic
7.18.1 Bavarian Nordic Corporation Information
7.18.2 Bavarian Nordic Description and Business Overview
7.18.3 Bavarian Nordic Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Bavarian Nordic Products Offered
7.18.5 Bavarian Nordic Recent Development
7.19 Celldex Therapeutics
7.19.1 Celldex Therapeutics Corporation Information
7.19.2 Celldex Therapeutics Description and Business Overview
7.19.3 Celldex Therapeutics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.19.4 Celldex Therapeutics Products Offered
7.19.5 Celldex Therapeutics Recent Development
7.20 ImmunoCellular Therapeutics
7.20.1 ImmunoCellular Therapeutics Corporation Information
7.20.2 ImmunoCellular Therapeutics Description and Business Overview
7.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.20.4 ImmunoCellular Therapeutics Products Offered
7.20.5 ImmunoCellular Therapeutics Recent Development
7.21 Incyte
7.21.1 Incyte Corporation Information
7.21.2 Incyte Description and Business Overview
7.21.3 Incyte Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.21.4 Incyte Products Offered
7.21.5 Incyte Recent Development
7.22 Dendreon Corporation
7.22.1 Dendreon Corporation Corporation Information
7.22.2 Dendreon Corporation Description and Business Overview
7.22.3 Dendreon Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.22.4 Dendreon Corporation Products Offered
7.22.5 Dendreon Corporation Recent Development
7.23 Agilent Technologies Inc.
7.23.1 Agilent Technologies Inc. Corporation Information
7.23.2 Agilent Technologies Inc. Description and Business Overview
7.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.23.4 Agilent Technologies Inc. Products Offered
7.23.5 Agilent Technologies Inc. Recent Development
7.24 Agenus Inc.
7.24.1 Agenus Inc. Corporation Information
7.24.2 Agenus Inc. Description and Business Overview
7.24.3 Agenus Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.24.4 Agenus Inc. Products Offered
7.24.5 Agenus Inc. Recent Development
7.25 Enzo Biochem, Inc.
7.25.1 Enzo Biochem, Inc. Corporation Information
7.25.2 Enzo Biochem, Inc. Description and Business Overview
7.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.25.4 Enzo Biochem, Inc. Products Offered
7.25.5 Enzo Biochem, Inc. Recent Development
7.26 Lonza Group
7.26.1 Lonza Group Corporation Information
7.26.2 Lonza Group Description and Business Overview
7.26.3 Lonza Group Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.26.4 Lonza Group Products Offered
7.26.5 Lonza Group Recent Development
7.27 Bio-Rad Laboratories, Inc.
7.27.1 Bio-Rad Laboratories, Inc. Corporation Information
7.27.2 Bio-Rad Laboratories, Inc. Description and Business Overview
7.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.27.4 Bio-Rad Laboratories, Inc. Products Offered
7.27.5 Bio-Rad Laboratories, Inc. Recent Development
7.28 Avantor, Inc.
7.28.1 Avantor, Inc. Corporation Information
7.28.2 Avantor, Inc. Description and Business Overview
7.28.3 Avantor, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.28.4 Avantor, Inc. Products Offered
7.28.5 Avantor, Inc. Recent Development
7.29 Spring Bank Pharmaceuticals, Inc.
7.29.1 Spring Bank Pharmaceuticals, Inc. Corporation Information
7.29.2 Spring Bank Pharmaceuticals, Inc. Description and Business Overview
7.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.29.4 Spring Bank Pharmaceuticals, Inc. Products Offered
7.29.5 Spring Bank Pharmaceuticals, Inc. Recent Development
7.30 Ferring Pharmaceuticals
7.30.1 Ferring Pharmaceuticals Corporation Information
7.30.2 Ferring Pharmaceuticals Description and Business Overview
7.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.30.4 Ferring Pharmaceuticals Products Offered
7.30.5 Ferring Pharmaceuticals Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Immuno-oncology Drugs Industry Chain Analysis
8.2 Immuno-oncology Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Immuno-oncology Drugs Distributors
8.3 Immuno-oncology Drugs Production Mode & Process
8.4 Immuno-oncology Drugs Sales and Marketing
8.4.1 Immuno-oncology Drugs Sales Channels
8.4.2 Immuno-oncology Drugs Distributors
8.5 Immuno-oncology Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
